Healios AG, a digital health startup that develops and validates digital biomarkers, has completed a pre-series A funding round to scale up and meet growing demand. Multiple investors and business angels in Switzerland participated in the round.
Healios AG embarked on a journey to digitise the monitoring of chronic conditions. Since 2018, the startup has been collaborating with a world-renowned Swiss academic research team in neurology at the University of Basel (RC2NB) to develop and validate novel digital biomarkers. The project has attracted the interest of global pharmaceutical companies and academic research teams both in EU and in the US.
Healios AG digital biomarkers cover five key neurological domains: movement, balance, dexterity, vision and cognition. Each domain can be measured through mobile-phone-based fun and interactive proprietary tests tailored to the research needs.
Based on this technology, the startup has launched a digital platform “Healios Science” to enable the creation and distribution of digital biomarkers through mobile apps known as “software medical device”. The first mobile app is called dreaMSMD which is CE-certified and aims to precisely and continuously monitor the neurological functions of multiple sclerosis (MS) patients. Further applications in stroke and mental health are in development and will be launched soon. Healios Science aims to provide a suite of medical apps to diagnose and monitor most patients affected by neurological conditions. Healios Science is currently in the market with patients and clinicians using it for research purposes.
To further enhance the technology, the company has recently secured substantial capital investment through its latest pre-series A financing round from multiple investors in Switzerland including Zühlke Ventures, the Lichtsteiner Foundation and many high-profile business angels.
Healios AG currently employs 30 people. “Our commercial traction demonstrates the value of our technology. Healios AG is an early growth start-up, and we are in the process of scaling up our operations and commercial team in order to serve our expanding customer base. Our solution is based on emerging new science which is now gaining interest from major market stakeholders. We also work closely with doctors and patients and soon also with insurance companies who support us in achieving our goal”, says Guilhem Dupont, Chairman & CEO of Healios AG.
(RAN)
Please login or sign up to comment.
Commenting guidelines